Graybug Vision, Inc. (NASDAQ:GRAY – Get Free Report) shares fell 8.6% during trading on Tuesday . The company traded as low as $0.52 and last traded at $0.52. 94,824 shares were traded during mid-day trading, an increase of 4,280% from the average session volume of 2,165 shares. The stock had previously closed at $0.5690.
Graybug Vision Stock Performance
The firm has a fifty day simple moving average of $1.25 and a 200-day simple moving average of $3.07. The company has a market capitalization of $816,920.00, a PE ratio of -0.30 and a beta of 1.20.
Graybug Vision Company Profile
Graybug Vision, Inc is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for retinal diseases. The company’s proprietary Depot Technology Platform is designed to deliver sustained-release formulations of biologically active agents directly to the back of the eye, with the goal of reducing treatment burden and improving patient outcomes. Graybug’s lead product candidate, GB-102, is a long-acting formulation of sunitinib malate being investigated for the treatment of wet age-related macular degeneration (wet AMD).
Featured Stories
Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.
